Real-World Clinical Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist on Mild-to-Moderate Diabetic Kidney Disease in Patients with Type 2 Diabetes: A Retrospective, Single-Arm Clinical Trial [Letter]
Letter
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
publication date
published in
Research
keywords
angiotensin receptor antagonist; dipeptidyl carboxypeptidase inhibitor; dulaglutide; glucagon like peptide 1 receptor agonist; metformin; sodium glucose cotransporter 2 inhibitor; adjuvant therapy; chronic disease; clinical effectiveness; clinical trial (topic); diabetic nephropathy; disease exacerbation; dose response; drug efficacy; evidence based practice; first-line treatment; human; hypoglycemia; Letter; lifestyle modification; mild to moderate diabetic kidney disease; mild to moderate diabetic kidney disease; non insulin dependent diabetes mellitus; outcome assessment; patient preference; practice guideline; prevalence; proteinuria; renal protection; retrospective study; risk factor
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info
start page
end page
volume
issue
